Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis
Objectives: To estimate stage-specific transition probabilities in individuals coinfected with
HIV and hepatitis C virus (HCV), to examine the effect of covariates on these rates, and to …
HIV and hepatitis C virus (HCV), to examine the effect of covariates on these rates, and to …
Increasing burden of liver disease in patients with HIV infection
Introduction of effective combined antiretroviral therapy has made HIV infection a chronic
illness. Substantial reductions in the number of AIDS-related deaths have been …
illness. Substantial reductions in the number of AIDS-related deaths have been …
World scientists' warning to humanity: a second notice
Background. The objective of this study was to determine the efficacy of pegylated interferon
(peg-IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV)–infected patients with …
(peg-IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV)–infected patients with …
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C Virus–monoinfected patients: a cohort …
Background: The incidence and determinants of hepatic decompensation have been
incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in …
incompletely examined among patients co-infected with HIV and hepatitis C virus (HCV) in …
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
JM Molina, C Orkin, DM Iser, FX Zamora, M Nelson… - The Lancet, 2015 - thelancet.com
Background Although interferon-free regimens are approved for patients co-infected with
HIV and genotype-2 or genotype-3 hepatitis C virus (HCV), interferon-based regimens are …
HIV and genotype-2 or genotype-3 hepatitis C virus (HCV), interferon-based regimens are …
Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression
Background. It is unclear whether coinfection with hepatitis C virus (HCV) increases mortality
in patients with human immunodeficiency virus (HIV) infection during the era of highly active …
in patients with human immunodeficiency virus (HIV) infection during the era of highly active …
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV
Context Human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV) disease
progression; however, the effect of liver disease stage and antiviral therapy on the risk of …
progression; however, the effect of liver disease stage and antiviral therapy on the risk of …
[PDF][PDF] Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
A few studies have assessed the observed fibrosis progression between serial liver biopsies
(LB) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)‐coinfected patients …
(LB) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)‐coinfected patients …
Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors
SB Missiha, M Ostrowski, EJ Heathcote - Gastroenterology, 2008 - Elsevier
The hepatic complications of chronic hepatitis C (CHC) usually occur only after progression
to cirrhosis has taken place. Progression to cirrhosis, however, is extremely variable and …
to cirrhosis has taken place. Progression to cirrhosis, however, is extremely variable and …
Advances in the treatment of HIV/HCV coinfection in adults
S Schlabe, JK Rockstroh - Expert opinion on pharmacotherapy, 2018 - Taylor & Francis
Introduction: Direct-acting antivirals (DAA) have revolutionized the modern treatment of
chronic hepatitis C (HCV). These highly efficacious, well-tolerated, all-oral HCV regimens …
chronic hepatitis C (HCV). These highly efficacious, well-tolerated, all-oral HCV regimens …